NAT GENET:癌细胞自杀开关

2017-03-21 wangzhe MedSci原创

有关人类生物学还有许多未解之谜,其中之一是,為什麼很多复杂的疾病,如糖尿病、高血压和精神疾病总是难以预先发现,有时也很难治癒。同样令人困惑的还有,為什麼同卵双胞胎其中之一患上了像癌症或抑鬱症这样的病,而另一个却安然无恙。

为什么很多复杂的疾病,如糖尿病高血压和精神疾病总是难以预先发现,有时也很难治癒。同样令人困惑的还有,为什么同卵双胞胎其中之一患上了像癌症或抑郁症这样的病,而另一个却安然无恙。 

近年来,人类发现了一个可以解开谜团的重要线索。人类基因组携带着至少400万个基因开关,这些基因开关位于曾被认為是垃圾的DNA片段上,但后来发现,它们在控制细胞、器官和其他组织的行为上起着关键作用。这一发现被认为是医学界和科学界的重大突破,对人类健康具有重大意义,很多复杂的疾病似乎就是由数百个基因开关的微小变化引起的。

此前在多种生物体中已经实现了基于RNA的感应开关并能够控制基因调节。虽然基于RNA遗传控制策略的潜在优势已经在临床应用中显示出来,但成功地将这些控制系统扩展到医疗应用中很少有报道。本研究中,实现了了人工合成的,基于RNA的核酶系统并将其应用到合理设计的细胞治疗中。茶碱敏感性的基于核酸酶的这一开关装置为肿瘤细胞中的自杀基因表达调节提供了强大的平台。此外,我们证明我们的合成控制开关能够有效地调节细胞在药物输入后的生存能力。我们基于RNA的这一开关系统能够:剂量依赖性微调转基因在哺乳动物细胞中的表达,解决了现有基因细胞的治疗的遗传控制方法的局限性。

原始出处:

Zhang Y, Wang J, Cheng H, et al. Conditional control of suicide gene expression in tumor cells with theophylline-responsive ribozyme[J]. Gene Therapy,Received 29 July 2016.doi:10.1038/gt.2016.78

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733831, encodeId=68131e3383103, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Mar 27 20:26:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686065, encodeId=f6cc168606548, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 27 07:26:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048791, encodeId=1cbd2048e9149, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 01 16:26:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881770, encodeId=e6e61881e7031, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 23 19:26:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252206, encodeId=7a97125220649, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Mar 23 02:26:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
    2017-03-27 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733831, encodeId=68131e3383103, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Mar 27 20:26:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686065, encodeId=f6cc168606548, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 27 07:26:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048791, encodeId=1cbd2048e9149, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 01 16:26:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881770, encodeId=e6e61881e7031, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 23 19:26:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252206, encodeId=7a97125220649, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Mar 23 02:26:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733831, encodeId=68131e3383103, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Mar 27 20:26:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686065, encodeId=f6cc168606548, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 27 07:26:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048791, encodeId=1cbd2048e9149, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 01 16:26:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881770, encodeId=e6e61881e7031, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 23 19:26:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252206, encodeId=7a97125220649, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Mar 23 02:26:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
    2017-10-01 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733831, encodeId=68131e3383103, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Mar 27 20:26:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686065, encodeId=f6cc168606548, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 27 07:26:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048791, encodeId=1cbd2048e9149, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 01 16:26:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881770, encodeId=e6e61881e7031, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 23 19:26:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252206, encodeId=7a97125220649, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Mar 23 02:26:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
    2017-04-23 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733831, encodeId=68131e3383103, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Mar 27 20:26:00 CST 2017, time=2017-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686065, encodeId=f6cc168606548, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Jan 27 07:26:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048791, encodeId=1cbd2048e9149, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 01 16:26:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881770, encodeId=e6e61881e7031, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Apr 23 19:26:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252206, encodeId=7a97125220649, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Mar 23 02:26:00 CST 2017, time=2017-03-23, status=1, ipAttribution=)]
    2017-03-23 yxch36

相关资讯

科学家发现衰老细胞和癌细胞中存在相同的蛋白质

【衰老和早期癌症新靶向】根据伦敦玛丽皇后大学的研究发现,蛋白质在老化细胞中担当着未知的角色,研究人员希望这一发现可以对衰老和早期癌症的治疗起到作用。

Cancer Cell:重大发现!科学家阐明癌细胞重编程血管促进癌症扩散的分子机理

血管在癌症的生长和扩散中都扮演着重要的角色,而且血管的内皮细胞和癌细胞彼此能够亲密接触,并且互相影响彼此,近日,刊登在国际杂志Cancer Cell上的一项研究报告中,来自德国癌症研究中心和海德堡大学的研究人员就对内皮细胞和癌细胞之间的相互作用进行了深入研究。 文章中,研究者惊人地发现,肿瘤的

石墨烯高级玩法:高度特异性杀伤癌细胞

尽管科学技术飞速发展,癌症检测方法及治疗方法都有迅猛的进展,但是癌症仍然是目前死亡率最高的疾病之一,其中的血液相关癌症(如白血病等)死亡率极高。目前癌症的常见治疗方法之一便是化疗,但是化疗存在一系列问题,如药物会在正常组织中富集、肿瘤药物浓度达不到有效浓度、系统毒性、无法监测疗效及产生多药耐药性等。其中对正常组织的毒副作用是一个最主要的问题,直接关乎病人的生存质量。纳米材料由于可以增加药物肿瘤富集

Nat Commun:癌细胞是“聪明的小混蛋”:脂肪代谢反而使其扩散加快

肝癌是全世界癌症相关死亡的第三大原因,是澳大利亚增长最快的癌症。来自UNSW的副教授Kyle Hoehn说:“许多人怀疑肝癌的致命性在于细胞代谢过程。人们认为这种脂肪生产在帮助癌细胞增殖中发挥重要作用”。由Hoehn领导的团队设法成功阻止转基因小鼠的肝细胞中的脂肪生成,存在意想不到的后果。不像团队预测的那样终止了癌细胞的生长,阻断这种代谢途径导致两倍多的肿瘤的出现。令人惊讶的结果在本周发表在Nat

Sci Sig:科学家阐明如何增强或抑制机体免疫反应的信号

作为免疫系统的“管理者”,T细胞能够与呈递病原体或癌细胞蛋白的其它细胞不断合作,但每个T细胞都会被重编程来识别仅仅一小部分蛋白片段(抗原),这就意味着,如果没有T细胞或其子代细胞的话,机体或许会花费很长时间来识别抗原;当T细胞识别抗原后,其会同抗原进行接触,这种最初的相互作用会促进T细胞对附近

Oncogene:靶向作用关键受体或可有效阻断卵巢癌转移

日前,一项刊登在国际杂志Oncogene上的研究报告中,来自伊利诺伊大学的研究人员通过研究发现,阻断卵巢癌细胞表面的一种关键蛋白或许就能有效抑制或降低卵巢癌向其它器官中扩散。 据美国癌症协会数据显示,每年在美国大约会有22440名女性会被诊断为卵巢癌患者,其中大约有1.5万名女性死于卵巢癌,因此卵巢癌